Wellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPH

Wellington Management Group LLP reduced its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 21.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,429 shares of the biopharmaceutical company’s stock after selling 43,062 shares during the period. Wellington Management Group LLP owned 0.31% of Theravance Biopharma worth $1,388,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Aquatic Capital Management LLC bought a new position in Theravance Biopharma during the fourth quarter valued at about $25,000. GAMMA Investing LLC increased its stake in shares of Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 3,281 shares during the period. R Squared Ltd increased its stake in shares of Theravance Biopharma by 636.6% in the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 10,822 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 142.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,670 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 7,452 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Theravance Biopharma in the fourth quarter worth about $119,000. 99.10% of the stock is currently owned by institutional investors.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Stock Down 0.6%

Shares of TBPH opened at $13.88 on Monday. Theravance Biopharma, Inc. has a 12-month low of $7.88 and a 12-month high of $14.30. The firm has a market capitalization of $699.00 million, a price-to-earnings ratio of 57.83 and a beta of 0.04. The stock’s 50-day moving average price is $11.80 and its 200 day moving average price is $10.30.

Wall Street Analyst Weigh In

TBPH has been the topic of a number of recent analyst reports. BTIG Research lifted their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, June 27th. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 15th. Jones Trading upgraded Theravance Biopharma to a “strong-buy” rating and set a $24.00 price objective on the stock in a research note on Tuesday, June 17th. Finally, Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Strong Buy” and a consensus price target of $21.33.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.